—A recent study provides genetic evidence linking a higher body mass index (BMI) to an increased risk of primary biliary cholangitis and autoimmune hepatitis but a decreased risk of primary sclerosing ...

Distinct lipid changes in primary biliary cholangitis may signal inflammation and fibrosis. Discover how these findings could ...

Intercept Pharmaceuticals has voluntarily withdrawn Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC) from the US market. The decision follows a request from the FDA.

While PBC progresses slowly and many patients do not experience symptoms during the early stages of disease, there are many symptoms to look out for. In later stages of disease, patients may ...

A major retrospective study shows that people with blood group A face a higher likelihood of autoimmune liver disease, especially primary biliary cholangitis, while those with blood group B appear ...